| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -59.1 | -3.6 |
| Net income | -59.1 | -3.6 |
| EPS (diluted, $ a share) | $-1.79 | $-0.61 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: LBRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lb Pharmaceuticals Inc: key numbers
- Share price
- $42.99Close, Nov 16
- Market cap
- $1.39B
- Shares outstanding
- 32.36MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lb Pharmaceuticals Inc
All →Lb Pharmaceuticals Financial Results
LB Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $403.8 million following a $150 million private placement. The company remains on track for a Phase 3 topline data readout for its lead schizophrenia candidate, LB-102, in the first half of 2027.
“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives whose expertise is directly aligned with our next phase of growth as we advance LB-102 across multiple neuropsychiatric indications and prepare for potential commercialization in schizophrenia.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
“Our recent R&D Day highlighted why we believe LB-102 has the potential to become the branded antipsychotic of choice, based on a differentiated profile with the potential to balance efficacy, tolerability, and simplicity of use.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
Lb Pharmaceuticals Executive Compensation
LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. Her compensation package includes a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus, and an inducement grant of 200,000 stock options vesting over four years.
- Counterparty
- Susan G. Kozauer, M.D.